Skip to content

Covered endovascular reconstruction of aortic bifurcation (CERAB) for extensive aortoiliac occlusive disease

Covered endovascular reconstruction of aortic bifurcation (CERAB) for extensive aortoiliac occlusive disease - CERAB-trial

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON48644
Enrollment
35
Registered
2019-03-07
Start date
2019-05-22
Completion date
Unknown
Last updated
2024-04-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Narrowing vascular disease

Interventions

CERAB-technique, as described in the introduction of the study protocol.

Sponsors

Rijnstate Ziekenhuis
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - Age 18 years or older - Provided written informed consent - Clinical necessity for treatment - Eligible anatomy for CERAB without the need for chimney*s - TASC-2 classification as assigned in the study protocol

Exclusion criteria

Exclusion criteria: - Patient is participating in another conflicting clinical study - Patient*s life expectancy

Design outcomes

Primary

MeasureTime frame
- Technical success is defined as successful implantation of the CERAB device without occlusion during the first 30-days after implantation and without conversion to open repair - Primary patency at 12 months

Secondary

MeasureTime frame
Technical: * Patency rates * Target vessel revascularization rate * Conversion to open surgery Clinical: * Freedom from Reinterventions * 30-day morbidity * Incidence of serious adverse events device or procedural related within the 3, 6 and 12 months post intervention period * Overall and reintervention-free survival * Clinical improvement, as measured by the Rutherford category *Patient reported outcomes including general health status, Quality of life and disease specific outcomes

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)